Janssen Pharmaceutical Inc.
NEWS
Pharma companies from across the globe provide updates on their pipelines and business.
FARE said the biomarker research project, which will be conducted at Janssen’s World Without Disease Accelerator, “has the potential to make a real and significant impact for the 32 million Americans living with food allergies.”
Janssen will assist with transferring the manufacturing rights of PRV-6527 to either Provention for continued development or assist in the transference of rights to a third party.
If approved by the European Commission, the daratumumab-VTd regimen would represent the first therapeutic option indicated for newly diagnosed patients who are eligible for a stem cell transplant in six years
Positive Opinion is based on data from the Phase 3 TITAN study which were published in The New England Journal of Medicine
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
It was a busy week for clinical trial announcements. Here’s a look.
ACR Annual Meeting: Janssen’s Tremfya Nails Primary Endpoints in 24-Week Psoriatic Arthritis Studies
Both DISCOVER 1 and DISCOVER 2 are evaluating Tremfya in adults with active psoriatic arthritis.
JOBS
IN THE PRESS